YAO-LIN LIUFUNG-RONG HUI-JONG WANGWEI-LI CHENYU-CHIH HOU2020-10-222020-10-2220110929-6646https://www.scopus.com/inward/record.uri?eid=2-s2.0-82255175691&doi=10.1016%2fj.jfma.2011.09.004&partnerID=40&md5=323046847249120354704a7fd5c8696bhttps://scholars.lib.ntu.edu.tw/handle/123456789/517815Background/Purpose: To compare the efficacy and safety of topical cromolyn between with and without preservative for the treatment of allergic conjunctivitis. Methods: A double-masked study was performed in patients with allergic conjunctivitis. Each cromolyn sodium 2% ophthalmic solution with or without 0.01% benzalkonium chloride (BAK) was randomized to apply on either eye. The efficacy and safety were evaluated every other week by a questionnaire about ocular itching, redness and foreign body sensation, and objective scores of conjunctival redness, chemosis, cornea erosion and discharge using slit-lamp biomicroscopy. An overall response was also rated by physician's impression. Results: A total of 37 subjects were enrolled in this study but only 33 completed the study. All of subjective questionnaire scores showed a significant improvement after treatment in both groups. Objective score of redness significantly decreased after treatment in either groups but not chemisos or discharge. After 4-week treatment, corneal erosion diminished significantly in the group without preservative but not in the group with 0.01% BAK. There was no significant difference between with and without 0.01% BAK groups in each subjective or objective score. No adverse effect related with medication was observed. Conclusion: Cromolyn 2 % ophthalmic solution was effective and safe to treat allergic conjunctivitis. A short-term use of cromolyn 2 % ophthalmic solution with 0.01% BAK would not cause any significant toxicity in patients with allergic conjunctivitis. Preservative-free cromolyn may be beneficial to the compromised eyes or eyes required of long-term medication. ? 2011.[SDGs]SDG3benzalkonium chloride; cromoglycate disodium; eye drops; adult; aged; allergic conjunctivitis; article; chemosis; clinical article; conjunctiva disease; conjunctiva redness; controlled study; cornea erosion; drug efficacy; drug safety; foreign body; hospital discharge; human; ocular pruritus; parallel design; questionnaire; randomized controlled trial; slit lamp; treatment outcome; treatment response; unspecified side effect; Adult; Benzalkonium Compounds; Conjunctivitis, Allergic; Cromolyn Sodium; Double-Blind Method; Humans; Mast Cells; Middle Agedjournal article10.1016/j.jfma.2011.09.004221183122-s2.0-82255175691